Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens —as a monotherapy, or in combination with everolimus, pembrolizumab, or other investigational agents— demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma (mRCC).
“Lenvatinib’s activity after immune checkpoint inhibitors (ICI) combination therapy in [RCC] remains unknown,” stated Javier Gavira, MD, Gustave Roussy, Villejuif, France, and coauthors. “We aimed to describe the real-world outcomes of patients with [mRCC] treated with lenvatinib after failure of the prior standard of care.”
This multicenter study included 133 patients with favorable, intermediate, or poor risk mRCC who had received prior treatment and were treated with lenvatinib alone (45.9%) or in combination with everolimus (33.8%), pembrolizumab (18%), or other investigational agents (2.3%). Primary end points included objective response rate (ORR) and time-to-treatment failure. Key secondary end points included disease control rate, overall survival (OS), and safety.
At analysis, the ORR was 29.1% and the median time-to-treatment failure was 6.2 months. The disease control rate was 67.7% and the median OS was 9.6 months. Toxicity was manageable, with 34.6% of all patients requiring dose modifications and 9.8% of patients discontinuing treatment. There was 1 toxicity-related death.
“Lenvatinib-based regimens were active and safe for heavily pre-treated patients with mRCC,” concluded Dr Gavira et al. “These findings provide evidence to support its use in daily practice.”
Source:
Gavira J, Auclin E, Rey-Cardenas M, et al. Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT). Eur J Cancer. Published online: March 26, 2025. doi: 10.1016/j.ejca.2025.115389
